STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract Lines 01-40
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Backgroud Lines 57-111
Objectives	3	State specific objectives, including any prespecified hypotheses	Backgroud Lines 112-116
Methods			
Study design	4	Present key elements of study design early in the paper	Methods Line 192-195
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods Subjects Lines 120-132
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	Methods Subjects Lines 120-132
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods Lines 146-189
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Methods Lines 160-189
Bias	9	Describe any efforts to address potential sources of bias	To calculate the sample size by PASS
Study size	10	Explain how the study size was arrived at	To calculate the sample size by PASS
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Methods Statistical analysis Lines 192-208
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Methods Statistical analysis Lines 192-208
		(*b*) Describe any methods used to examine subgroups and interactions	Not applicable
		(*c*) Explain how missing data were addressed	Not applicable.There was no missing data in this study
		(*d*) If applicable, describe analytical methods taking	Not applicable

		account of sampling strategy	
		(*e*) Describe any sensitivity analyses	Not applicable
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Results Table1 Lines 851-861
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Results Table1 Lines 851-861
		(b) Indicate number of participants with missing data for each variable of interest	Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures	Results Table1-4 Figure1-3
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results Lines 217-277 Tables 1-2, Table 4 Figures 1-3
		(*b*) Report category boundaries when continuous variables were categorized	Not applicable
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
Discussion			
Key results	18	Summarise key results with reference to study objectives	Conclusion Lines 518-529
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Limitations Lines 509-516
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion Lines 278-516
Generalisability	21	Discuss the generalisability (external validity) of the study results	Conclusion Lines 518-529
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Fundings were described on the title page

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.